(NASDAQ: RGNX) Regenxbio's forecast annual revenue growth rate of 32.02% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.62%.
Regenxbio's revenue in 2025 is $161,318,000.On average, 14 Wall Street analysts forecast RGNX's revenue for 2025 to be $9,820,372,453, with the lowest RGNX revenue forecast at $7,942,762,193, and the highest RGNX revenue forecast at $16,484,901,725. On average, 14 Wall Street analysts forecast RGNX's revenue for 2026 to be $14,579,954,999, with the lowest RGNX revenue forecast at $6,976,873,713, and the highest RGNX revenue forecast at $21,665,668,346.
In 2027, RGNX is forecast to generate $18,635,370,418 in revenue, with the lowest revenue forecast at $10,652,109,756 and the highest revenue forecast at $25,450,250,256.